ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Salmeterol (SN408D) for Adult Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00950794
Recruitment Status : Completed
First Posted : August 3, 2009
Last Update Posted : August 7, 2009
Sponsor:
Information provided by:
GlaxoSmithKline

Brief Summary:
To demonstrate the efficacy (non-inferiority) of Salmeterol 50mcg bid (100mcg/day), compared with Hokunalin (tulobuterol) tape 2mg once a day, in terms of improvement in pulmonary function (peak expiratory flow: PEF) in a randomized, double-blind, parallel-group comparative study in adult patients with bronchial asthma on ICS 400mcg/day of FP equivalent.

Condition or disease Intervention/treatment Phase
Asthma Bronchial Asthma Drug: Salmeterol(SN408D) Drug: Hokunalin (tulobuterol) tape Phase 4

Detailed Description:

Primary To demonstrate the efficacy (non-inferiority) of Salmeterol 50mcg bid (100mcg/day), compared with Hokunalin (tulobuterol) tape 2mg once a day, in terms of improvement in pulmonary function (peak expiratory flow: PEF) in a randomized, double-blind, parallel-group comparative study in adult patients with bronchial asthma on ICS 400mcg/day of FP equivalent.

Secondary

  • To evaluate the efficacy of Salmeterol , compared with Hokunalin (tulobuterol) tape in terms of asthma symptoms recorded in the asthma diary.
  • To evaluate the safety of Serevent compared with Hokunalin (tulobuterol) tape.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 367 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Study of Salmeterol (SN408D) for Adult Asthma - Clinical Study of Salmeterol Compared With Hokunalin (Tulobuterol) Tape -
Study Start Date : September 2003
Actual Primary Completion Date : February 2005
Actual Study Completion Date : February 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Hokunalin(tulobuterol) tape
Hokunalin(tulobuterol) tape: long-acting Beta2-agonist
Drug: Hokunalin (tulobuterol) tape
Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
Experimental: Salmeterol(408DP-02)
Salmeterol(408DP-02):long-acting Beta2-agonist
Drug: Salmeterol(SN408D)
Salmeterol(SN408D):long-acting Beta2-agonist



Primary Outcome Measures :
  1. Change in morning PEF [ Time Frame: 8 week ]

Secondary Outcome Measures :
  1. Use of short acting beta agonist [ Time Frame: 8 week ]
  2. Adverse event [ Time Frame: 8 week ]
  3. Evening PEF [ Time Frame: 8 week ]
  4. Symptom score [ Time Frame: 8 week ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • For entry into run-in period (Visit 1)

A subject will be considered eligible for inclusion in this study only if all of the following criteria apply:

  1. Males or females aged >= 15 years at the time of giving informed consent.
  2. Subjects who are able to give a written informed consent to participation in the study.

    However, if a subject is aged < 20 years at the time of giving informed consent, a written informed consent should be obtained from the subject and his/her legally acceptable representative.

  3. Outpatients.
  4. Subjects who had been diagnosed as asthma at least 6 months prior to Visit 1.
  5. Subjects who have been receiving ICS 400mcg/day of FP equivalent for at least 8 weeks prior to Visit 1.

    • For entry into the treatment period (Visit 2)

A subject will be considered eligible for entering the treatment period only if he/she completes the run-in period and meets all of the following criteria:

  1. Subjects who meet both of the following criteria in terms of pulmonary function.

    • Has a mean morning PEF during the last 7 days (at least 4 days) prior to Visit 2 is >= 40% of the predicted value.
    • Has at least 2 days with a diurnal variation in PEF of >= 15% during the run-in period, or had been confirmed and recorded reversibility of >= 15% using rapid-acting inhaled beta2 agonists within 3 months prior to Visit 1 (including Visit 1).
  2. Subjects who have >= 70 % compliance with asthma medication during the run-in period.
  3. Subjects who were able to measure peak flows correctly during the run-in period, in the investigator's/subinvestigator's judgment.
  4. Subjects who were able to keep the asthma diary correctly during the run-in period, in the investigator's/subinvestigator's judgment.

Exclusion Criteria:

  • A subject will not be eligible for inclusion in this study if any of the following criteria apply at Visit 1 or Visit 2:

    1. Subjects who have received injected steroids, injected ACTH, or oral steroids within four weeks of Visit1 or during run-in period.
    2. Subjects who have received xanthines (oral, injected, suppository), beta2 agonists other than rescue medication (rapid-acting inhaled beta2 agonists), or inhaled anti-cholinergics during the run-in period.
    3. Subjects with respiratory disease other than asthma (e.g., chronic bronchitis, emphysema, bronchiectasis, pulmonary fibrosis, lung cancer, sarcoidosis, and old tuberculosis) which, in the judgment of the investigator/subinvestigator, are likely to affect efficacy evaluation.
    4. Subjects with uncontrollable diabetes mellitus, hypertension, heart disease, or hyperthyroidism, who are inappropriate for this study in the judgement of the investigator/sub investigator.
    5. Subjects who are unsuitable for this study in the judgment of the investigator/subinvestigator based on 12-lead ECG findings at Visit 1.
    6. Subjects who are regularly using medications containing the following ingredients:

      beta-blockers, alpha/beta-blockers

    7. Subjects who have received immunosuppressive medications excluding Tacrolimus ointment.
    8. Subjects who are receiving catecholamines.
    9. Subjects with atopic dermatitis who are inappropriate for this study in the judgment of the investigator/subinvestigator.
    10. Subjects who had or are suspected to have had hypersensitivity to any of the investigational products.
    11. Subjects who received the last dose of other investigational drugs in the past 30 days.
    12. Subject who are currently pregnant, possibly pregnant, lactating or willing to become pregnant during the study period.
    13. Subjects who consume alcohol or drugs excessively the opinion of the investigator/subinvestigator.
    14. Subjects who are judged by the investigator/subinvestigator to have Step 4 asthma (severe persistent), referring to "GINA2002" and "J-GL2003".
    15. Subjects who are judged by the investigator/subinvestigator to be inappropriate for this study for any other reasons.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00950794


Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00950794     History of Changes
Other Study ID Numbers: 112376
First Posted: August 3, 2009    Key Record Dates
Last Update Posted: August 7, 2009
Last Verified: August 2009

Keywords provided by GlaxoSmithKline:
Long acting beta2-agonist

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Salmeterol Xinafoate
Tulobuterol
Terbutaline
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Sympathomimetics
Tocolytic Agents
Reproductive Control Agents